Tonix Pharmaceuticals Holding Corp. - 8-K Filing
Tonix Pharmaceuticals announced an agreement effective June 1, 2026, with a second leading group purchasing organization (GPO) providing coverage for its drug TONMYA® to approximately 17 million U.S. commercial lives—adding to the existing 35 million covered under another GPO agreement from May 1, 2026. Total commercial access now reaches ~52 million individuals (~29% of total commercial lives in the U.S.), with Medicaid coverage available for an additional ~75 million beneficiaries. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $TNXP